Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.61 |
| ▸ | MAOA | P21397 | 3/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | HTR2B | P41595 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11056699 | 1.00 | PNMT (0.62) | PNMTTAAR1MAOASLC6A2SLC6A4 | |
| SCHEMBL11059954 | 1.00 | PNMT (0.62) | PNMTTAAR1MAOASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL11675476 | 0.98 | PNMT (0.60) | PNMTTAAR1MAOASLC6A2SLC6A4 | |
| Sulfuric Acid SCHEMBL11053544 | 0.89 | PNMT (0.56) | PNMTTAAR1MAOASLC6A2SLC6A4 | |
| SCHEMBL153431 | 0.87 | MAOA (0.52) | PNMTTAAR1MAOASLC6A2SLC6A4 | |
| SCHEMBL29403479 | 0.87 | MAOA (0.52) | PNMTTAAR1MAOASLC6A2SLC6A4 | |
| SCHEMBL24152546 | 0.86 | TAAR1 (0.73) | PNMTTAAR1MAOASLC6A2SLC6A4 | |
| SCHEMBL13387614 | 0.86 | TAAR1 (0.73) | PNMTTAAR1MAOASLC6A2SLC6A4 | |
| Maleic Acid SCHEMBL11675427 | 0.85 | TAAR1 (0.50) | PNMTTAAR1MAOASLC6A2SLC6A4 | |
| SCHEMBL8281166 | 0.83 | ADRB2 (0.52) | PNMTTAAR1MAOASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4477470-A | ANTIEDEMIC AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1984-10-16 | — | — | US | claimed |
| CN-106573956-A | Auristatin derivatives and conjugates thereof | 诺华股份有限公司 | 2017-04-19 | — | — | CN | disclosed |
| CN-104703965-A | Alpha hydroxy amides | MERCK PATENT GMBH | 2015-06-10 | — | — | CN | disclosed |
| US-20110021467-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| US-7842711-B2 | Indazolecarboxamide derivatives for the treatment and prevention of malaria | SANOFI-AVENTIS (FR) | 2010-11-30 | — | — | US | disclosed |
| EP-1511721-B1 | GUANIDINO PHENYLALANIN COMPOUNDS USED AS UROKINASE INHIBITORS | WILEX AG (DE) | 2009-07-01 | — | — | EP | disclosed |
| US-7504403-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7482342-B2 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2009-01-27 | — | — | US | disclosed |
| EP-1716150-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20070185187-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2006-01-05 | — | — | US | disclosed |
| WO-2005099703-A1 | USE OF INDAZOLECARBOXAMIDE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT THAT IS INTENDED FOR THE TREATMENT AND PREVENTION OF PALUDISM | SANOFI-AVENTIS (FR) | 2005-10-27 | — | — | WO | disclosed |
| US-20050187223-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005070932-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| EP-1549620-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | Sanofi-Aventis (FR) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004031158-A1 | INDAZOLECARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF AS CDK1, CDK2 AND CDK4 INHIBITORS | SANOFI-AVENTIS (FR) | 2004-04-15 | — | — | WO | disclosed |
| US-4477470-A | ANTIEDEMIC AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1984-10-16 | — | — | US | disclosed |
| US-4477470-A | ANTIEDEMIC AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1984-10-16 | — | — | US | disclosed |
| US-4477470-A | ANTIEDEMIC AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1984-10-16 | — | — | US | disclosed |
| US-4015011-A | HYPERTENSIVES | BOEHRINGER INGELHEIM GMBH (DT) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185187-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | CYP3A43, CYP3A5, SIRT5 | PNMT 1932/4885TAAR1 4627/4885MAOA 1543/4885 |
| US-20050187223-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MUSK, MAPT | PNMT 2264/4885TAAR1 2835/4885MAOA 2747/4885 |
| US-20110021467-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | CYP3A43, CYP3A5, SIRT5 | PNMT 1932/4885TAAR1 4627/4885MAOA 1543/4885 |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | CDK2, CDK1, CDK4 | PNMT 3524/4885TAAR1 2306/4885MAOA 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.